CN112921093B - lnc-AGO2功能性表达抑制剂在制备治疗乳腺癌的药物中的应用 - Google Patents
lnc-AGO2功能性表达抑制剂在制备治疗乳腺癌的药物中的应用 Download PDFInfo
- Publication number
- CN112921093B CN112921093B CN202110307744.8A CN202110307744A CN112921093B CN 112921093 B CN112921093 B CN 112921093B CN 202110307744 A CN202110307744 A CN 202110307744A CN 112921093 B CN112921093 B CN 112921093B
- Authority
- CN
- China
- Prior art keywords
- lnc
- ago2
- breast cancer
- functional expression
- expression inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 72
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 71
- 239000003112 inhibitor Substances 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 241000713666 Lentivirus Species 0.000 claims abstract description 10
- 238000010459 TALEN Methods 0.000 claims abstract description 9
- 108091030071 RNAI Proteins 0.000 claims abstract description 8
- 230000009368 gene silencing by RNA Effects 0.000 claims abstract description 8
- 108091027967 Small hairpin RNA Proteins 0.000 claims abstract description 7
- 239000004055 small Interfering RNA Substances 0.000 claims abstract description 7
- 239000013598 vector Substances 0.000 claims abstract description 7
- -1 ZFN Proteins 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 230000006801 homologous recombination Effects 0.000 claims abstract description 6
- 238000002744 homologous recombination Methods 0.000 claims abstract description 6
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims abstract 2
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 20
- 230000006907 apoptotic process Effects 0.000 abstract description 8
- 230000035755 proliferation Effects 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 8
- 238000000338 in vitro Methods 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 6
- 238000002054 transplantation Methods 0.000 abstract description 6
- 206010006189 Breast cancer in situ Diseases 0.000 abstract description 3
- 201000005389 breast carcinoma in situ Diseases 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 108091033409 CRISPR Proteins 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000000440 bentonite Substances 0.000 description 4
- 229910000278 bentonite Inorganic materials 0.000 description 4
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 108091027963 non-coding RNA Proteins 0.000 description 3
- 102000042567 non-coding RNA Human genes 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005717 Laminarin Substances 0.000 description 2
- 229920001543 Laminarin Polymers 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000003655 absorption accelerator Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006718 epigenetic regulation Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了lnc‑AGO2功能性表达抑制剂在制备治疗乳腺癌的药物中的应用，属于生物医药技术领域。所述lnc‑AGO2功能性表达抑制剂为RNAi、shRNA慢病毒、sgRNA、ZFN、TALEN元件或同源重组载体。本发明通过lnc‑AGO2在乳腺癌细胞中的表达明显升高，可以用于乳腺癌的检测，建立了体外lnc‑AGO2敲除乳腺癌细胞模型、体内lnc‑AGO2敲乳腺癌除原位移植瘤模型系列实验研究，阐述了lnc‑AGO2可明显抑制乳腺癌细胞的增殖能力，并且明显促进乳腺癌细胞的调亡，敲除lnc‑AGO2可用于预防或治疗乳腺癌，从而可制备lnc‑AGO2功能性表达抑制剂治疗乳腺癌。
Description
技术领域
本发明属于生物医药技术领域，具体涉及lnc-AGO2功能性表达抑制剂在制备治疗乳腺癌的药物中的应用。
背景技术
乳腺癌是乳腺上皮细胞在多种致癌因子的作用下，发生增殖失控的现象，是导致女性癌症死亡的主要原因。世界卫生组织国际癌症研究机构(IARC)发布了2020年全球最新癌症负担数据：2020年全球新发癌症病例1929万例。其中一个最明显的变化是乳腺癌新发病例数的快速增长达226万，首次正式取代肺癌(220万)成为全球第一大癌症，占所有新增癌症患者的11.7%。乳腺癌是严重威胁全世界女性健康的第一大恶性肿瘤。在每年新发乳腺癌病例中，约3%-10%的妇女在确诊时即有远处转移。早期患者中，30%可发展为晚期乳腺癌，晚期乳腺癌患者5年生存率仅为 20%；而乳腺癌细胞在化疗过程中产生的耐药会导致很多患者在化疗后仍会出现在短期内复发或转移。
最近的研究表明在哺乳动物基因组中只有不到2%的基因能够编码蛋白，其它大约98%的基因都编码成非编码RNA。非编码RNA根据其长度，一般分为两类，一类为非编码小RNA(sncRNA，Small non-coding RNA)，其转录长度少于200个核苷酸，另一类为长链非编码RNA(Long non-coding RNA，lncRNA)，被广泛的定义为转录长度超过200个核苷酸并且没有表观编码能力的RNA。LncRNA具有复杂的二级结构、三级结构，能够与蛋白质、RNA、DNA结合，因此lncRNA为miRNA、mRNA、蛋白质或者其复合物进行复杂的相互作用提供了平台。目前越来越多的证据显示，lncRNA在基因转录、转录后调控、RNA剪切、翻译、表观遗传调控等过程中都发挥着重要作用，并与乳腺癌的生物学行为关系密切。
lnc-AGO2位于8号染色体，该基因产生一个长的非编码RNA，其长度为9346bp，在转录的表观遗传调控中发挥作用，作为一种新发现的在乳腺癌中异常表达的lncRNA，其调控机制及病理作用迄今尚未见任何报道。
发明内容
本发明通过荧光定量PCR检测到lnc-AGO2在乳腺癌细胞中的表达明显升高，故检测lnc-AGO2的表达水平可用于诊断乳腺癌。本发明通过体外慢病毒稳定转染实验成功敲除lnc-AGO2可明显抑制乳腺癌细胞的增殖能力，并且明显促进乳腺癌细胞的调亡。同时建立体内lnc-AGO2敲乳腺癌除原位移植瘤模型，结果显示乳腺肿瘤体积明显小于对照组，与体外试验一致。因此，敲除lnc-AGO2可用于预防或治疗乳腺癌，为乳腺癌的诊断和治疗提供新的思路和方案。
为此，本发明的目的在于研究lnc-AGO2功能性表达抑制剂用于制备预防或治疗乳腺癌的药物组合物，lnc-AGO2功能性表达抑制剂为针对lnc-AGO2的RNAi、针对lnc-AGO2的shRNA慢病毒、针对lnc-AGO2的sgRNA（配合CRRSPR/Cas9使用）、针对lnc-AGO2的ZFN（配合ZFN技术使用）、针对lnc-AGO2的TALEN元件（配合TALEN技术使用）、或者针对lnc-AGO2的同源重组载体（利用Cre/LoxP系统或来自酵母的FLP-frt系统），以及包括与抑制剂配伍的其他药类以及药学上可接受的载体，包括：稀释剂、赋形剂如乳糖、氯化钠、葡萄糖、尿素、淀粉、水等、填充剂如淀粉、蔗糖等；粘合剂如单糖浆、葡萄糖溶液、淀粉溶液、纤维素衍生物、藻酸盐、明胶和聚乙烯吡咯烷酮；湿润剂如甘油；崩解剂如干淀粉、海藻酸钠、海带多糖粉末、琼脂粉末、碳酸钙和碳酸氢钠；吸收促进剂如季铵化合物、十二烷基硫酸钠等；表面活性剂如聚氧化乙烯山梨聚糖脂肪酸酯、十二烷基硫酸钠、硬脂酸单甘油酯、十六烷醇等;致湿剂如甘油、淀粉等；吸附载体如淀粉、乳糖、斑脱土、硅胶、高岭土和皂粘土等；润滑剂如滑石粉、硬脂酸钙和镁、聚乙二醇、硼酸粉末等。
本发明通过lnc-AGO2在乳腺癌细胞中的表达明显升高，可以用于乳腺癌的检测，建立了体外lnc-AGO2敲除乳腺癌细胞模型、体内lnc-AGO2敲乳腺癌除原位移植瘤模型系列实验研究，阐述了lnc-AGO2可明显抑制乳腺癌细胞的增殖能力，并且明显促进乳腺癌细胞的调亡，敲除lnc-AGO2可用于预防或治疗乳腺癌，从而可制备lnc-AGO2功能性表达抑制剂治疗乳腺癌。
附图说明
图1为实施例1中荧光定量PCR检测lnc-AGO2在乳腺癌细胞MCF-7，MDA-MB-231中的表达情况。
图2 为实施例2中肿瘤图及肿瘤体积统计图。
具体实施方式
下面结合附图和具体实施例对本发明作进一步详细说明，但不应理解为对本发明的限制。在不背离本发明精神和实质的情况下，对本发明方法、步骤或条件所作的修改或替换，均属于本发明的范围。实施例中未注明具体条件的实验方法及未说明配方的试剂均为按照本领域常规条件。
本发明主要解决的技术问题是提供了lnc-AGO2功能性表达的抑制剂用于制备预防或治疗乳腺癌的药物组合物的用途，并为乳腺癌的治疗提供指导方案。所述抑制剂是针对lnc-AGO2的RNAi。
所述lnc-AGO2的核苷酸序列如SEQ ID NO.1所示。
lnc-AGO2的RNAi序列(正义链，反义链，5'→3)为：
UCCAUUUCGAAGAAAUUGGCC (SEQ ID NO.4)
CCAAUUUCUUCGAAAUGGACA (SEQ ID NO.5)。
本发明建立了体外乳腺癌细胞培养体系模拟人体内环境。通过临床相关数据库分析各基因的相关性，最终发现lnc-AGO2在乳腺癌细胞中高表达，故选定进入下一步的实验。在之后建立了体外lnc-AGO2敲除乳腺癌细胞模型、体内lnc-AGO2敲乳腺癌除原位移植瘤模型系列实验研究，从而研究制备lnc-AGO2功能性表达抑制剂。
其中乳腺癌细胞选用的是MCF-7/MDA-MB-231细胞。
之前的多篇文献表明，现有技术中实现乳腺癌早发现早治疗仍是提高乳腺癌患者预后效果的重要途径，并且目前对乳腺癌精准治疗药物研究较少。因此，本发明提供了lnc-AGO2在乳腺癌细胞中的表达明显上调，可用于检测乳腺癌。
实施例1
本发明设计了针对lnc-AGO2在乳腺癌细胞中的表达实验，旨在发现lnc-AGO2是否在乳腺癌细胞中为高表达。通过荧光定量PCR检测乳腺癌细胞MCF-7、MDA-MB-231中lnc-AGO2的表达情况。
具体实验步骤如下：
荧光定量PCR实验步骤：
1、应用Trizol试剂(Invitrogen，Carlsbad，USA)从细胞和组织样品中取总RNA。
吸尽6孔板中乳腺癌细胞MCF-7，MDA-MB-231细胞的培养液，每孔加入1ml Trizol，使其覆盖
细胞，再用吸管或加样器吹打3次，细胞应完全裂解，然后转移至离心管中。
在装有裂解物
的离心管中加入0.2mL的氯仿(1mL Trizol加入0.2mL氯仿)，振荡器上充分振荡混匀20秒，
室温放置5分钟。12000 rpm 4℃离心10分钟，然后吸取含总RNA的上层水相至一新的离心管
中，每毫升Trizol约可吸取0.6mL上层水相。有机相和中间层含有DNA和蛋白质，应避免触
及。
加入和上层水相等体积的异丙醇，颠倒数次混匀，室温沉淀5分钟。12000 rpm 4℃ 离
心15分钟，在管底可见RNA沉淀。弃上清，按每毫升Trizol加入1mL 75%乙醇，轻轻颠倒混匀，
以清洗RNA沉淀。12000 rpm 4℃离心2分钟，弃去液体，小心勿丢弃RNA沉淀。室温倒置晾干
5-10分钟。
溶解：加入适量DEPC处理水使RNA沉淀溶解。存放于-80℃。
2、应用M-MLV逆转录酶合成第一链cDNA。
3、在总体积为 20μL的SYBR Green PCR Master Mix(Roche，Germany)中进行实时定量 PCR(qPCR)。所有反应均一式两份进行。使用2–△△CT法方法计算lnc-AGO2的相对表达量。用于磷酸化AKT的PCR引物在Invitrogen 合成。GAPDH作为内参照。lnc-AGO2引物序列如表1。
表1 lnc-AGO2引物序列
结果如图1所示，lnc-AGO2在乳腺癌细胞中的表达明显上调，而且在高侵袭性细胞MDA-MB-231中的表达量相对较高，在低侵袭性细胞MCF-7中的表达量相对较低
实施例2
据文献报道，除shRNA慢病毒外，还有多种技术手段可以同样实现制lnc-AGO2的功能性表达，或抑制涉及lnc-AGO2的下游的物质功能性表达，进而起到抑制lnc-AGO2用于预防或治疗乳腺癌的功能。这些技术手段包括但不限于其他RNAi技术(通过其他siRNA抑制lnc-AGO2的功能性表达)、成簇规律间隔短回文重复(CRRSPR)技术(使用一段序列特异性向导RNA分子(sequence-specific guide RNA，sgRNA)引导核酸内切酶到靶点处，从而完成基因组的编辑，特别的以CRISPR/Cas9技术为代表)、锌指核酸酶(ZFN)技术(通过加工改造ZFN的锌指DNA结合域， 靶向定位于不同的DNA序列)、转录激活样效应因子核酸酶(TALEN)技术(通过DNA识别模块 将TALEN元件靶向特异性的DNA位点并结合，然后在FokI核酸酶的作用下完成特定位点的剪切，并借助于细胞内固有的同源定向修复(HDR)或非同源末端连接途径(NHEJ)修复过程完成特定序列的插入(或倒置)、删失及基因融合)、利用同源重组载体敲除基因的技术(如 Cre/LoxP系统或来自酵母的FLP-frt系统，利用基因同源重组原理，用设计的同源片段替代靶基因片段，从而达到基因敲除的目的)。
因此，本发明的目的在于研究lnc-AGO2功能性表达抑制剂用于制备预防或治疗乳腺癌的药物组合物，lnc-AGO2功能性表达抑制剂为针对lnc-AGO2的RNAi、针对lnc-AGO2的shRNA慢病毒、针对lnc-AGO2的sgRNA（配合CRRSPR/Cas9使用）、针对lnc-AGO2的ZFN（配合ZFN技术使用）、针对lnc-AGO2的TALEN元件（配合TALEN技术使用）、或者针对lnc-AGO2的同源重组载体（利用Cre/LoxP系统或来自酵母的FLP-frt系统），以及包括与抑制剂配伍的其他药类以及药学上可接受的载体，包括：稀释剂、赋形剂如乳糖、氯化钠、葡萄糖、尿素、淀粉、水等、填充剂如淀粉、蔗糖等；粘合剂如单糖浆、葡萄糖溶液、淀粉溶液、纤维素衍生物、藻酸盐、明胶和聚乙烯吡咯烷酮；湿润剂如甘油；崩解剂如干淀粉、海藻酸钠、海带多糖粉末、琼脂粉末、碳酸钙和碳酸氢钠；吸收促进剂如季铵化合物、十二烷基硫酸钠等；表面活性剂如聚氧化乙烯山梨聚糖脂肪酸酯、十二烷基硫酸钠、硬脂酸单甘油酯、十六烷醇等;致湿剂如甘油、淀粉等；吸附载体如淀粉、乳糖、斑脱土、硅胶、高岭土和皂粘土等；润滑剂如滑石粉、硬脂酸钙和镁、聚乙二醇、硼酸粉末等。
本发明通过shRNA慢病毒转染乳腺癌细胞，成功敲除lnc-AGO2并构建为表达能力高的稳转细胞株进行体外实验，其中感染RNAi慢病毒的MDA-MB-231细胞为siRNA-lnc-AGO2组，感染对照慢病毒MDA-MB-231细胞为siRNA-NC组。同时建立体内lnc-AGO2敲乳腺癌除原位移植瘤模型，结果均显示可明显抑制乳腺癌细胞的增殖能力，增殖能力明显减弱，且明显促进乳腺癌细胞的调亡，细胞凋亡量增加。表明敲除lnc-AGO2可有效用于预防或治疗乳腺癌。
具体实验步骤如下：
为了进一步研究lnc-AGO2功能性表达抑制剂用于制备预防或治疗乳腺癌的药物组合物，建立了体外lnc-AGO2敲除乳腺癌细胞模型、体内lnc-AGO2敲乳腺癌除原位移植瘤模型系列实验研究，从而去验证敲除lnc-AGO2是否能够抑制乳腺肿瘤的生长，且同时促进乳腺癌细胞凋亡。为此，将三组雌性BALB/C裸鼠予以成功敲除lnc-AGO2并构建为表达能力高的稳转MDA-MB-231细胞株行背部皮下注射法。三组裸鼠均成瘤，通过游标卡尺定期测量裸鼠原位移植瘤的长径及短径，成瘤时间平均为10天，根据瘤体体积绘制生长曲线。待小鼠自然死亡或成瘤后20天断颈处理小鼠，取瘤称重。
结果如图2所示，敲除lnc-AGO2的转染病毒组（siRNA-lnc-AGO2）肿瘤体积显著低于空载组（siRNA-NC）和空白对照组（Control）（p<0.01），提示敲除lnc-AGO2后对乳腺癌治疗作用意义。因此，敲除lnc-AGO2可明显抑制乳腺癌细胞的增殖能力，增殖能力明显减弱，且明显促进乳腺癌细胞的调亡，细胞凋亡量增加。表明敲除lnc-AGO2可有效用于预防或治疗乳腺癌。同时，为研究lnc-AGO2功能性表达抑制剂用于制备预防或治疗乳腺癌的药物组合物提供重要依据。
本发明的研究结果将为乳腺癌的药物研究及其精准治疗提供新的思路，将在促进人类的健康事业方面发挥重要的作用。
序列表
<110> 南通大学
<120> lnc-AGO2功能性表达抑制剂在制备治疗乳腺癌的药物中的应用
<130> 20210322
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 9346
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
ttttaatact aaaaacatta atagaccaaa catctccagc tgggtcagct gcacaccttt 60
gtacatgtct gatgattcag agtttaaatg gctgtagtta caatttctca ggtaaacaat 120
tgttttctca aatttttacc aatccctgca ttattaggat aaattttgag acagtgtaaa 180
aacctcaaag tacagtaggg taagtcccag ccctgttcac gtgaaagcca gaggtggccc 240
ttccccggca tctgatcgtc tgatcatgtg ggtgcctggg gccttgccac ccttccctgt 300
ccactgctgc ccccctgggc ctgtcaagat ttgaggggtg cccactcgct ggctttgtcc 360
ccatcccact gttaagtaag gtgtgccttg ctttaagcaa actgaatgtg aaaattatgt 420
gtagaagtct gggtttgttt aaaagaaaaa ctgggatttt atctcatctc tttaaaagag 480
gtctcccaat tcgatttctg tactgggact cttcctggtg tgtttttaca tgttcacttt 540
ttaaaaacat tgatgtactc ccatcctttt accactaccc tatcacattt gacaagttct 600
tgctgtaatg acgacgcaat taacgaacac caggggagcg gtggaaagct gccctcgtgt 660
gtgagccctt cggtgacgca aagccaccgt cctgttgttt tgtgtgtcct aagctcagat 720
tttcctggtt tggataaatt ttgtaaaact gggcatagct gtacttttag aaagggatcg 780
ttttccttaa gttttggttt tctctggttc aagcagtctt tacatgcagc cttttgattg 840
cacatcaggg tctccctttt cttttccaga tgatgttgct tttcggtggt ggtctcacac 900
tcctttgaat gaatgtttgc actctagaac cacaaacgat gcgtgaccat tgtacagctt 960
gcccaagagg gaactgttgg aagcaggcag tgacctccac gctgtttgtt tgaggctgac 1020
ctaaactgct atcactaatg tttacccccg tgacggagtg cccattagaa cagatcatgt 1080
cagttcagtt cctgtagtgg ggttagtagg tggggggttt tattgttgtt gttatttgtt 1140
acttttattg ctgttaaatg caaatattgc tatttatttt ttcctttctg ctctggtttg 1200
gtttggccga cacagatatt ccagtgcatg tggtacctaa tggatatgat agaaattatt 1260
tccccaactt ttataaattg cctaatgttt accttcaagt ttgctggatg atttattttt 1320
gaaagccaca aatgtgattt ttctggatga attgtttttc ttatatatgc agcaatgtaa 1380
ttttacattg atctgcgggg tggtttaaat tttattttta caaggcagtt tttcagtcaa 1440
attatatatt tgatacaata cgctaggata gaccggccac acgtcaggca gccgggacac 1500
cggagtgtcc ccaggaggcc tttggggctg gggtggcccg tggcttgttc cctgcgcctc 1560
tgggaactgg atgagtcctt cggcgggact gtgacccgct ggacagttaa aaggattttt 1620
catgggcatt ttcctacaca taaggcagtt ccattaggag gagctttaga agtcgacata 1680
atccagacag tggacaatcc cagtggccca gacaagccat acgacatttt cctgtgacct 1740
ctctctgacc catctctcac gctcatgaga aaaggaatgt acaataaata gaaacagaaa 1800
cttcctcagt gctcatgcgc ctcacttgca gaacgtgagt atttcattta tgtttgaagc 1860
ccttccccaa agtgaccgag gagttgcact ctagctgccg tgccagcagt ctcgtctgct 1920
gtgacgcttc tcggtgcgga tgcagtgcac ctgtgacttt gtcatggggg tgcccctgtt 1980
acacacacac acgctgactc ttttttatga ggaaaatctt cgactcaaaa taattgcact 2040
gattttttga caacttcttt ttacgatgtc ccacttcgca tctgctgtac ttgtttgaga 2100
tgattgtaaa tagatttgtg gtaggagaag tgacatgaat gcaacacgtg gctctgttgt 2160
ggagacactg cctcgtattc agtattatgt gttaaagttg tgtggactta actctgttcc 2220
gccctttagc ttcgtgtctg ttgaccattt atgaaggaca agttcgcctc attttctttt 2280
tcttctgaag ggaagttcta gatcggttac taggagaaca tggtctcttg gtgcctgatg 2340
atttagtcct aagcagactc gttgcagtct tgtgaacact gttgtggtct gtttgattcc 2400
tcgtcgctta ccgtggctct ccaaagcatg gtctttgagt tccacccagc ctgggacagt 2460
ccagacggga ggcatctgct ccgcctgcta ctaggacgca agggcctcct tgcatctctg 2520
tggtcagagt catcttaaag ccatgaggtt actgtcgtgt caaagctgtc atttgtgccc 2580
gttattttgc tggagtagca gcgtgtgctg tagcccccgt gtgtcactct gtggtcaggc 2640
taccctgtgt cacacccagc aagaagtttt tcagccccag accagtctgt gtgtgtgtcc 2700
gagtcacacc agtgccatta cggtgccctc gcttatgctt ctttcagtat gttttgccat 2760
gttattgtct aaagtgaatg tattggctta gccaaatcac tacagaaggt ggttcctaaa 2820
taccttttag tttaaaaaaa aatgcagata aaggctacct ctgaattctc aatagattca 2880
tcatgtttgc tcttaagtgt agctgtccac actgaaaaca gccaatatgt tgcctgaata 2940
aactgaattg tgaacatcta tctgttcagt tctggcttga aaatgtgtgt gccatactgt 3000
gacccacggg cagcccctcc tcctctactg tgtcaggtgg accagggtca cctctgttct 3060
gcgcagcttt gagattctag gattctacgg ccggcacgaa tggcatggga gggttctctg 3120
cacgggacgg cataacggca tgccatcctt caggctggca ggagcctgcg caggtgtggc 3180
aaaatcttga aacagcctgt gtcctgcctg gcttttcact ttcctattta atataagaaa 3240
gcactttttt ttctgcttta cctacaaatg ggttgaaaat ggcctcctct gtcctctcct 3300
ctcttttata cactctgtaa aatcacaaag gtgcttcaac accgactgtc atgcaaataa 3360
tacatttaaa atagttgcat ggtttcaaag acaatgcaga cgtaattggc ctttgacttt 3420
gggacctcgg gttactctca ctccctactg caaaacaaac taagggttga aagcaaagca 3480
ttctgttcaa atccagggcc ctttgtttga aaagaacaca gggcccacag ctggtgtttt 3540
gaagtagaag ttcccactag tggcgcagtg gaccgtctga tgcagacttg caggaagtcg 3600
gtcctgggag gctctgaaca cccctccctg tgattaacca ctttgctgtc agaaatgtca 3660
ttttcccata cactgtgctg tgggcccggg gcctccttcg cttctttctt tgggttccat 3720
atgttgcccg atcttgaggt tagcgctcgc cccaatttct ccatgagttt actctgagtt 3780
gacaggcgat gatctgacag ttggaggtgt ctgggtgttt ggaggtggcc ccgttctcat 3840
gttggctgct catcagacat tgagtttggc cccggcggtt ctactacgtc actacctgga 3900
agcaattgcc tttaacactc tgctgtttgg ggtttcgatg ctttttatgc tgcgttgcgt 3960
gctttcattc cggaagagct aagtgtcctt tgcagtctct ctgagaatgt tttgtaattc 4020
tgccgccacg ctgttctgtg cggaccgacc tcaagaggct tgggcccccg tgggtgtccc 4080
actgcctgcc ggcccagggt acaggctgct tgggtccgct gggctggcct tgggctgtca 4140
gaatctggtc cagggtgttt cgaggggaca ctgcacagcc gctcgcccct cgactcagtc 4200
atgggagctg cagcacgcag atccaccgca agcttcctgc acgcgcatct ccggaatgct 4260
gcgctgggcc ctcccaccat cttcgcgttt gtgagaattt actcagaagt gagagaactg 4320
aagattcctg gtgcttttgt taacacgttt ctatcttatt ggttggtgtg gaaatgttag 4380
atgtgttgtt aggtttttaa atgctgtggg tggtatgatt aaagggttaa gtcctcacct 4440
cagcccccag cccccttttg gggggtagga agaggctgag ttatctccta tttaaaacct 4500
ccttggattt aagtagttca gagttaaagc taaaacacca aatattaact ctttccccca 4560
agtgtctcca ggaactggac gttggggcca ttcttattca gttctttctg tagctccaag 4620
gtccttaaaa tgagtgagtt gatcccaaga acaccccaca gcaccaacca gcagggcaca 4680
gtgcaagcga cttcatagat cggggtgctc gtgtaggggt ccggggctcc tttgaactct 4740
gggagttgtg tgcgcagtct tgggtgggag acggcaggtc cctctgtccc aagaagctgg 4800
tggtgccaag gccttcctct gtctccatca gtgccagcct gatcgcgttc tggaagaccc 4860
agtctcagac tctgtgcctt taaagtccgg tcctcagtgt cctttcagaa tcatgttggg 4920
gctgcgtttc tctggggaac taagcctgtg ccattccaca aggcaggcgt ggacctccag 4980
ccttggaagc tttctttccg ctcctcagcc cctgacttgt aaactgtgat gccatgcagt 5040
ctggagccgc gggggacgca ctcggtctca ttgcggaaaa cacttggttc cagtcgtgtg 5100
gtttctccca taccctgacc aagtccacct ctgccaggat tgcaggagat tggtgcaaga 5160
cccatctctt atgcattgac catgaccatc agcaaagcct ggtggtcttg ttctcatagt 5220
cactcgagaa gaatatttat tgtaatggaa gtagattttt taaaaaagga attggaatca 5280
tgtctttgta gaatgtgtgt gtgtgaagtc ctcagctgta aggtgctatt cagtcctgtg 5340
acccttattt tggaatgctc ttcattactg ttgctctgtt ttgtgacttc ctgggaaacc 5400
gcttactttg gtgtggtgtc accttgagct gtgcacatag gacaccagtt ttgacttaac 5460
ctaacaggca gtttttatct ctagcttttt caagccaggt attgagcagt ttcttggcca 5520
atggcctgag aaaccacctg tccctgtcaa ggggtgattt tattggtttt aagtggggaa 5580
gtaatcccat gtacttattt cttaaatacc taggaagttc ttcttggtgg ctcctcttgg 5640
ccctcccctc tttctccccc aacccaccat cctgcaaggc aaggaatggc ctctccctcc 5700
acagaggcaa cggctgcaga gggagcactg tggctgccat cccagttcct cttcaaagcc 5760
aaacagacac gcgtgactca aatcctacag tatggagggt ggcgttgcat tgaaattcca 5820
ggcctgagtt tgatagtgga ttttaatgta gttgttaaag gtatgaattc atgttttata 5880
actgtagagg caagcaagtt tttatttttt aaaaagtttt gagagaataa tttataagtt 5940
tctgtgcagc aaagtggcta attactcatt aaatacagga aaagaatgta gtatctaaat 6000
ccagcttttt cttacctctg gtacacttca gattacttac ctaatacata ttgagggctt 6060
ttaaccctta gttttatcaa tttttctagt tttattttat ttttataaaa taattgaaaa 6120
agaaccaaaa atgaattcag aagttccata gatggatttt tgccccttct taattttctc 6180
ccacaatgaa aacattttag aagacatttt gaatcaaaat gtattatgac cattgaaagt 6240
tctctatttt ctaagaagct gagcagctcc aagggcctcg tttcaggtgg tactctatgt 6300
attgtctgtg ggcttgtttc tacctgtaca gtggaaccat gtgaccatgt cttgtgcttg 6360
caatatagaa accatgcagt gctgttttgt gaattggcag tttctgtata aactcttatt 6420
tatatacatt ggcctctctg tatgattttc catttgctac atgaattgta aaattaatta 6480
taaaattata gtacctgcta aatacaattc tgaggcttca tgtcattgtc tttagttgaa 6540
taccatgctg tgtgtcttga agatgtccac gcttgcatga tgctaggtgg caatgccact 6600
ttaaattaag ccttaatcag atgttaaatt tgtgagtttc agagtatgca aaaatattag 6660
gcagagtgag tgtaaactgt tcagatcaag atgctgtatc ataattcaag ttattttttt 6720
ctggagttaa agggaagcat tcagtgatac acctctctct ctctctctct ctctccccct 6780
ctcccccctc cccctccctc tctctgtctc tgtctctgtc tctctctctc tctcttgtct 6840
agcttggcta tggccatagc ttgatgaaaa tggaccattg tgcatttctg tgacagtcaa 6900
aaagacctgt tctaaaagtc ttgcgacttt ttcagggttt tttttttttt tcatgtttct 6960
tttttttttt cccctccagt ctgagatttc tgtgtggctg atggagagtg tgatttgggc 7020
gtaggtctta tttgcaaacc tgctcatgtt ctaagctttc ttcaggtagt accacctgtc 7080
atcgcttctg catatgattt aaatggattt ttgtttttat aaaagtatca taaatttaga 7140
gataaaatgg aggggaccca gctttcttta caatgtggat ctacctcagt taaacagttg 7200
ggtgctatta ctaagtctgt caaattaaat tggaaaaagt aaccaaacag tgagatacaa 7260
ctccacatga aacttgaaat tgtaatttcc gtttatttaa tgatattttt atttatttgt 7320
gccttttatg ttgaacccca atgcattgaa aaaattcagt atgaaacagt acatatttta 7380
tttatattac aggtgggaga aaagtccaat tggtcatgga atttgataga cttttcccca 7440
gccaactgct acagtgtatt ataatcccga ctgcccccct gtgaaaagaa aaaaaaaaat 7500
gtccaagagc aaatttaaca ttttacaaac aataaagtcc aaactcctct atgcacatat 7560
ttatagctta tcacttcatt ttctgtgcca gtgaaggggt ggccagaaaa aaaatcccaa 7620
gtaccctcat cattgctttt ctagccattc atgccccctc ttcctctggc acattttcta 7680
agagtttatt tcataagcag caaacggact gttgtcgatt tcatctctcc tgacctacct 7740
ggtggaggtg ctaatggcca tggacagaaa ggggcgagcc agagctcgtg gctttgtgga 7800
ggcagaggcc tgcattcagc agcggccctg tgtgcctgta agttaggaag gctttctgac 7860
aggtaagaaa atgagatagg ttgatgactt accatgcttt tatatttggc agtttacaat 7920
tctagacttt tcctactatg gcgatctttt tttacttaat tctttggagg taacaatatt 7980
ttggagtctt aagaatttga ttttatacca ataagaaata aaaattaggg atctttcctg 8040
tagtatatag ttttactatt ttaaagagat ctctgaattt tacaagagaa ccaacattcc 8100
ttaatggcag aactttgaaa gttgatttgg gaggcttttt gctgcaggat ctcaaaaata 8160
gagagagaga tgattctact taaatgtttt taattttcta acttccatca ggttgatact 8220
taagctctat tttgtaaaga gtaaatcatc ctttagtatg ctgcataaga tgatcagcat 8280
tcttgcactt tctcagtaat aagacgtgcc gggcaattgg ctccccagga cgcattgtgt 8340
ttttaaccta acgagaggac tttggggcag gtgattaaat ttatataggt acctcaagaa 8400
aaagaacctg aatatgctgc attttctttc tttagctttt acatgtagca ttttgttttg 8460
cttttgttat ttttgttttg atatatgctt tttggacccc aatagactgt tgaaagaaat 8520
ttaaaaatta ctcttgtagg gatatagtat ccttaaaaaa taaaaattta aaaaaattta 8580
aaaaaattgc tgcaatatct ggctcgaagg ttgccctata ttagaataat actttagcca 8640
aatacacctg aggaggcaga cactgtgttt ataagcagac aataatgttc tgaatccttc 8700
ctgttcatgc tgctttctta attcatttct ccatgtcatc aagaggttgg ataacttatt 8760
tctaagctca aggttaaaaa tcatgtcacc tttttttttt tcccccaaca cagacctcag 8820
aaaaattgcg attgaggaag tagcatgatc ctaaatgtgt tgctgaaatc aggcagcccg 8880
agcctctggt ctctccagag agcccgtctt cacatttctc tattcctcag cactcacccg 8940
aaactgaaca gatggggagt ggtcttgatt gtcaagataa aactggtgaa gaaagctaaa 9000
tgctgagaaa ctgagcatct attgtcgtgt ttaagcttag ctgggtcctt tctagtttgt 9060
ttttacagct tactaggtga agtagtttgc actatttttg caataaattc atggaaaacc 9120
taacagttac ttgttttgtt tcttactgtg tgtatataaa ctaatactaa aagtttggca 9180
tagtgttttt tcacctcctt acataacccc taacatgcac agaatgctgt aaatctgata 9240
aaatatgatg tgaatgatat tttataaagt tattttgtat ggtgtcaatt ttgttttgcc 9300
tcatagtatg tcagcaaaaa attaaataaa agtcctccta tttaca 9346
<210> 2
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
gttgcttttc ggtggtggtc 20
<210> 3
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
agctgtacaa tggtcacgca 20
<210> 4
<211> 21
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 4
uccauuucga agaaauuggc c 21
<210> 5
<211> 21
<212> RNA
<213> 人工序列(Artificial Sequence)
<400> 5
ccaauuucuu cgaaauggac a 21
Claims (3)
1.lnc-AGO2功能性表达抑制剂在制备治疗乳腺癌的药物中的应用，所述lnc-AGO2的核苷酸序列如SEQ ID NO.1所示。
2.根据权利要求1所述的应用，其特征在于：所述lnc-AGO2功能性表达抑制剂为RNAi、shRNA慢病毒、sgRNA、ZFN、TALEN元件或同源重组载体。
3.根据权利要求1所述的应用，其特征在于：所述治疗乳腺癌的药物还包括与抑制剂配伍的其他药类以及药学上可接受的载体。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110307744.8A CN112921093B (zh) | 2021-03-23 | 2021-03-23 | lnc-AGO2功能性表达抑制剂在制备治疗乳腺癌的药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110307744.8A CN112921093B (zh) | 2021-03-23 | 2021-03-23 | lnc-AGO2功能性表达抑制剂在制备治疗乳腺癌的药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112921093A CN112921093A (zh) | 2021-06-08 |
| CN112921093B true CN112921093B (zh) | 2022-06-03 |
Family
ID=76175487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110307744.8A Active CN112921093B (zh) | 2021-03-23 | 2021-03-23 | lnc-AGO2功能性表达抑制剂在制备治疗乳腺癌的药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112921093B (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107475441A (zh) * | 2017-10-13 | 2017-12-15 | 中国医学科学院肿瘤医院 | 一种预测乳腺癌患者对at方案新辅助化疗的反应性的生物标记物 |
-
2021
- 2021-03-23 CN CN202110307744.8A patent/CN112921093B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107475441A (zh) * | 2017-10-13 | 2017-12-15 | 中国医学科学院肿瘤医院 | 一种预测乳腺癌患者对at方案新辅助化疗的反应性的生物标记物 |
Non-Patent Citations (2)
| Title |
|---|
| 严德文等.长链非编码RNA CasC7对宫颈癌细胞增殖的影响.《温州医科大学学报》.2018,(第02期),第17-21页. * |
| 黄炎华等.长链非编码RNA在乳腺癌中的研究进展.《海南医学》.2018,(第08期),第99-102页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112921093A (zh) | 2021-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MacFarlane et al. | MicroRNA: biogenesis, function and role in cancer | |
| WO2016077125A1 (en) | Alternative nucleic acid molecules containing reduced uracil content and uses thereof | |
| EP2632932A2 (en) | Compositions and methods for activating expression by a specific endogenous mirna | |
| WO2024012300A1 (zh) | 一种基因编辑的方法和用途 | |
| CN113249380B (zh) | 靶向covid-19新冠病毒的反义寡核苷酸、natac嵌合分子及其应用 | |
| CN109022461B (zh) | 一种PTEN基因的上游开放阅读框45aa-uORF核苷酸序列及其编码的多肽的应用 | |
| US20230416747A1 (en) | Safe harbor loci | |
| CN106244593B (zh) | 一种调节鹿茸茸皮快速生长的microRNA及其应用 | |
| CN112921093B (zh) | lnc-AGO2功能性表达抑制剂在制备治疗乳腺癌的药物中的应用 | |
| CN112813033A (zh) | 一种胰岛素和白介素-10双基因修饰重编程间充质干细胞及其制备方法与应用 | |
| Yang et al. | MicroRNAs and regenerative medicine | |
| CN112852965B (zh) | lnc-ZNF100-5功能性表达抑制剂在制备治疗乳腺癌的药物中的应用 | |
| EP3981473A1 (en) | Therapeutic agent for cancer | |
| CN109022442B (zh) | 一种可有效抑制骨肉瘤生长的生物重组型miR124-3p | |
| Gao et al. | lncRNA TRPM2-AS promotes colorectal cancer progression by regulating miR-22-3p and FSTL1 | |
| CN111643668A (zh) | LncRNA-LOC100294145功能性表达的抑制剂的用途 | |
| CN113230268B (zh) | 一种非编码小rna基因、载体和细胞在制备抑制乳腺癌的药物中的用途 | |
| Wang et al. | Effectiveness of lentivirus-mediated RNA interference targeting mouse tumor necrosis factor α in vitro and in vivo | |
| CN115927611A (zh) | 一种乳腺癌的生物标志物及其应用 | |
| Jagielski et al. | A contemporary review of snoRNAs in cardiovascular health: RNA modification and beyond | |
| CN110652522B (zh) | miR-2052在制备抗肝癌药物中的应用 | |
| CN114042160B (zh) | Ctd-2256p15.2及其编码微肽作为靶点在开发肿瘤治疗药物中的应用 | |
| CN111004848B (zh) | Fbxl6作为靶点在制备抗肿瘤药物中的应用 | |
| CN107604065B (zh) | 一种肝癌miRNA标记物 | |
| CN117625779A (zh) | 一种用于诊断和治疗乳腺癌的生物标志物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240403 Address after: Room 110-113, Building 2, No. 58 Chongchuan Road, Nantong City, Jiangsu Province, 226000 Patentee after: Mark Desen Nutrition Technology (Jiangsu) Co.,Ltd. Country or region after: China Address before: 226019 Jiangsu Province, Nantong City Chongchuan District sik Road No. 9 Patentee before: NANTONG University Country or region before: China |